Key Drivers
- Margin strength
- Cash generation
- Moderate leverage
AIAI Summary
Illumina's core business and margins are improving, but the stock's rerating to ~37.5x earnings means the key question is no longer whether the franchise is intact but whether clinical consumables growth and new product adoption can outrun a now-stretched valuation without any execution slip.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin strength
- •Cash generation
- •Moderate leverage
ILMN combines strong margins, solid cash flow, and manageable leverage, but the stock looks expensive at current multiples and offers a less compelling risk-reward.
Price Behavior
Key Price Behavior Insights:
- •Rally fade
- •Resistance capped
- •Support test
ILMN has cooled into a corrective phase over the last month after a sharp rally, with $200–$205 resistance capping upside and $188–$190 support needing to hold to keep the rebound intact.
Sharp surge from about $184.68 to $205.10, then repeated pullbacks from resistance
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Momentum High
- •Mixed Ownership
Illumina posted a solid Q2 beat with revenue up 9.5% and EPS above estimates, which fueled fresh momentum and bullish ratings even as institutional ownership was mixed and merger-related transaction news added to the catalyst mix.
The strong quarterly results and improving technical sentiment likely support near-term upside, though investor focus may stay on execution and deal-related developments
Similar Companies in Healthcare
Other companies in the same sector with AI ratings